TCBPW Historical Balance Sheet

TCBPW Stock  USD 0.01  0.00  0.000002%   
Trend analysis of TC BioPharm plc balance sheet accounts such as Total Stockholder Equity of 3.2 M, Property Plant And Equipment Net of 3.2 M, Accounts Payable of 1.2 M or Cash of 2.3 M provides information on TC BioPharm's total assets, liabilities, and equity, which is the actual value of TC BioPharm plc to its prevalent stockholders. By breaking down trends over time using TC BioPharm balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining TC BioPharm plc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether TC BioPharm plc is a good buy for the upcoming year.

TC BioPharm Inventory

(1.49 Million)

  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TC BioPharm plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

About TCBPW Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of TC BioPharm plc at a specified time, usually calculated after every quarter, six months, or one year. TC BioPharm Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of TC BioPharm and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which TCBPW currently owns. An asset can also be divided into two categories, current and non-current.

TC BioPharm Balance Sheet Chart

At this time, TC BioPharm's Other Stockholder Equity is fairly stable compared to the past year. Total Liabilities is likely to climb to about 10.4 M in 2025, whereas Short and Long Term Debt Total is likely to drop slightly above 1.5 M in 2025.

Total Assets

Total assets refers to the total amount of TC BioPharm assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in TC BioPharm plc books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on TC BioPharm balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of TC BioPharm plc are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.
Most accounts from TC BioPharm's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into TC BioPharm plc current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TC BioPharm plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
At this time, TC BioPharm's Other Stockholder Equity is fairly stable compared to the past year. Total Liabilities is likely to climb to about 10.4 M in 2025, whereas Short and Long Term Debt Total is likely to drop slightly above 1.5 M in 2025.
 2022 2023 2024 2025 (projected)
Short and Long Term Debt Total2.5M1.8M1.6M1.5M
Total Assets11.3M8.9M10.3M10.0M

TC BioPharm balance sheet Correlations

-0.45-0.3-0.350.480.18-0.02-0.50.18-0.20.310.17-0.440.310.49-0.050.130.05-0.540.460.1-0.290.42-0.040.610.11
-0.450.580.82-0.94-0.010.330.96-0.110.1-0.14-0.010.68-0.14-0.09-0.30.010.170.11-0.480.040.91-0.810.13-0.28-0.15
-0.30.580.92-0.38-0.67-0.30.35-0.750.470.63-0.670.920.63-0.70.27-0.71-0.550.71-0.480.60.41-0.15-0.540.32-0.74
-0.350.820.92-0.63-0.49-0.140.66-0.590.410.35-0.490.920.35-0.510.14-0.51-0.320.52-0.390.510.67-0.4-0.40.13-0.62
0.48-0.94-0.38-0.63-0.27-0.61-0.96-0.190.20.36-0.28-0.450.36-0.130.57-0.29-0.450.090.620.29-0.950.96-0.380.51-0.17
0.18-0.01-0.67-0.49-0.270.880.20.98-0.9-0.781.0-0.73-0.780.93-0.840.990.98-0.91-0.09-0.90.32-0.520.76-0.640.97
-0.020.33-0.3-0.14-0.610.880.470.85-0.85-0.630.89-0.38-0.630.74-0.980.870.93-0.71-0.52-0.890.6-0.80.8-0.640.85
-0.50.960.350.66-0.960.20.470.11-0.05-0.420.20.48-0.420.08-0.40.230.38-0.05-0.41-0.160.92-0.890.27-0.510.07
0.18-0.11-0.75-0.59-0.190.980.850.11-0.87-0.780.98-0.79-0.780.89-0.810.990.94-0.89-0.07-0.930.2-0.450.77-0.620.99
-0.20.10.470.410.2-0.9-0.85-0.05-0.870.56-0.90.670.56-0.790.83-0.84-0.880.760.30.86-0.290.43-0.610.56-0.89
0.31-0.140.630.350.36-0.78-0.63-0.42-0.780.56-0.780.521.0-0.60.51-0.83-0.820.58-0.060.75-0.310.54-0.590.89-0.77
0.17-0.01-0.67-0.49-0.281.00.890.20.98-0.9-0.78-0.72-0.780.92-0.850.990.98-0.91-0.11-0.910.32-0.530.78-0.640.97
-0.440.680.920.92-0.45-0.73-0.380.48-0.790.670.52-0.720.52-0.740.36-0.72-0.590.75-0.340.660.4-0.18-0.450.28-0.8
0.31-0.140.630.350.36-0.78-0.63-0.42-0.780.561.0-0.780.52-0.60.51-0.83-0.820.58-0.060.75-0.310.54-0.590.89-0.77
0.49-0.09-0.7-0.51-0.130.930.740.080.89-0.79-0.60.92-0.74-0.6-0.740.910.87-1.00.13-0.720.23-0.350.7-0.330.85
-0.05-0.30.270.140.57-0.84-0.98-0.4-0.810.830.51-0.850.360.51-0.74-0.82-0.880.70.570.86-0.570.76-0.830.53-0.81
0.130.01-0.71-0.51-0.290.990.870.230.99-0.84-0.830.99-0.72-0.830.91-0.820.97-0.9-0.07-0.910.3-0.540.81-0.660.97
0.050.17-0.55-0.32-0.450.980.930.380.94-0.88-0.820.98-0.59-0.820.87-0.880.97-0.85-0.2-0.890.49-0.670.77-0.720.93
-0.540.110.710.520.09-0.91-0.71-0.05-0.890.760.58-0.910.750.58-1.00.7-0.9-0.85-0.180.69-0.190.31-0.670.3-0.83
0.46-0.48-0.48-0.390.62-0.09-0.52-0.41-0.070.3-0.06-0.11-0.34-0.060.130.57-0.07-0.2-0.180.37-0.520.63-0.330.3-0.15
0.10.040.60.510.29-0.9-0.89-0.16-0.930.860.75-0.910.660.75-0.720.86-0.91-0.890.690.37-0.230.55-0.830.74-0.97
-0.290.910.410.67-0.950.320.60.920.2-0.29-0.310.320.4-0.310.23-0.570.30.49-0.19-0.52-0.23-0.910.27-0.440.16
0.42-0.81-0.15-0.40.96-0.52-0.8-0.89-0.450.430.54-0.53-0.180.54-0.350.76-0.54-0.670.310.630.55-0.91-0.580.66-0.44
-0.040.13-0.54-0.4-0.380.760.80.270.77-0.61-0.590.78-0.45-0.590.7-0.830.810.77-0.67-0.33-0.830.27-0.58-0.50.79
0.61-0.280.320.130.51-0.64-0.64-0.51-0.620.560.89-0.640.280.89-0.330.53-0.66-0.720.30.30.74-0.440.66-0.5-0.66
0.11-0.15-0.74-0.62-0.170.970.850.070.99-0.89-0.770.97-0.8-0.770.85-0.810.970.93-0.83-0.15-0.970.16-0.440.79-0.66
Click cells to compare fundamentals

TC BioPharm Account Relationship Matchups

TC BioPharm balance sheet Accounts

202020212022202320242025 (projected)
Total Assets7.3M8.0M11.3M8.9M10.3M10.0M
Short Long Term Debt Total2.6M15.9M2.5M1.8M1.6M1.5M
Other Current Liab3.1M9.6M7.3M2.5M2.8M5.1M
Total Current Liabilities4.2M20.6M9.2M4.8M5.5M9.4M
Total Stockholder Equity(3.3M)(16.6M)331.3K2.7M3.1M3.2M
Property Plant And Equipment Net4.6M3.7M3.3M2.6M2.4M3.2M
Current Deferred Revenue2.0M2.0M1.3M(305.3K)(274.8K)(261.1K)
Net Debt1.8M14.3M(2.4M)(661.5K)(595.3K)(565.5K)
Retained Earnings(19.9M)(33.5M)(33.4M)(38.8M)(35.0M)(36.7M)
Accounts Payable638.4K1.4M882.4K1.8M2.1M1.2M
Cash748.0K1.6M4.8M2.5M2.8M2.3M
Non Current Assets Total5.0M4.2M3.8M3.2M2.9M3.6M
Cash And Short Term Investments748.0K1.6M4.8M2.5M2.8M2.3M
Net Receivables1.2M1.5M1.8M1.2M1.1M1.4M
Common Stock Shares Outstanding11.2M7.8M13.7M123.6M142.1M149.2M
Liabilities And Stockholders Equity7.3M8.0M11.3M8.9M10.3M10.0M
Non Current Liabilities Total6.4M4.0M1.8M1.5M1.3M1.3M
Capital Lease Obligations3.0M2.9M2.1M1.8M1.6M2.1M
Inventory(1.2M)(1.5M)(1.8M)(1.2M)(1.4M)(1.5M)
Other Current Assets230.7K811.3K836.1K4.1M4.7M4.9M
Total Liab10.6M24.6M11.0M6.2M5.6M10.4M
Net Invested Capital(3.3M)(9.8M)627.8K2.7M3.1M3.2M
Property Plant And Equipment Gross6.9M6.7M6.5M6.8M6.1M5.4M
Total Current Assets2.2M3.9M7.4M5.7M6.6M5.2M
Capital Stock1.8M195.5K397.5K2.1K1.9K1.8K
Net Working Capital(2.0M)(16.7M)(1.7M)950.3K1.1M1.1M
Short Term Debt442.7K7.6M981.5K305.3K351.1K333.6K
Intangible Assets423.8K483.6K553.0K615.2K707.4K523.9K
Common Stock194.6K195.5K397.5K2.1K1.9K1.8K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for TCBPW Stock Analysis

When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.